Does spending for subspecialty care in advanced-stage melanoma matter: Are greater access costs actually associated with increased use of immune therapy and improved survival among patients with low income? - Park SS; Verm RA; Park DD; Abdelsattar ZM; Luchette FA; Baker TB; Baker MS (Surgery, 2026)